natgillin/translations-raw huggingface dataset:
The frequency of adverse reactions is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Pogostost neželenih učinkov: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The AUC of the predominant metabolite accounted for approximately 2-3% of AUC of telavancin. 
AUC prevladujočega metabolita je znašal približno 2-3 % AUC-ja telavancina.
Creatinine clearance* (ml/min) 
Očistek kreatinina* (ml/min)
VIBATIV should be used only in situations where it is known or suspected that other alternatives are not suitable (see sections 4.3, 4.4, 4.8 and 5.1). 
Zdravilo VIBATIV se lahko uporablja le v primerih, ko je znano oz. ko se sumi, da druge možnosti niso ustrezne (glejte poglavja 4.3, 4.4, 4.8 in 5.1).
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. 
Po potrebi je treba poiskati nasvet strokovnjaka, ko je lokalno prevladovanje odpornosti tolikšno, da je delovanje učinkovine vsaj pri nekaterih vrstah okužb vprašljivo.
VIBATIV can only be used when other antibiotics are not suitable. 
Zdravilo VIBATIV lahko uporabljamo le, kadar drugi antibiotiki niso primerni.
Activated partial thromboplastin time 
Aktiviran parcialni tromboplastinski čas
The potential risk for humans is unknown (see section 4.6). 
Potencialno tveganje za človeka ni znano (glejte poglavje 4.6).
Detailed information on this medicine is available on the European Medicines Agency website: 
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila:
if you are suffering from heart disorders. 
Če trpite zaradi okvar srca.
Infusion related reactions can be limited if the daily dose is infused over a 1 hour period. 
Reakcije, povezane z infundiranjem, je mogoče omejiti, če je dnevni odmerek infundiran v času 1 ure.
if you notice a change in your hearing. 
Če zaznate spremembo v sluhu.
In the absence of compatibility studies, this medicine must not be mixed with other medicines. 
Zaradi pomanjkanja študij kompatibilnosti se to zdravilo ne sme mešati z drugimi zdravili.
Recommendations for dose adjustment can be found in section 4.2. 
Priporočila glede prilagoditev odmerka se nahajajo v poglavju 4.2.
Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Store in a refrigerator (2-8°C). 
Shranjujte v hladilniku (2-8 °C).
• The existence and scope of the pregnancy register and details of how to enter patients into it. 
• Obstoj in obseg registra nosečnosti ter podatki, kako vključiti bolnice vanj.
The final protocol for the PASS should be provided to the CHMP by 30 April 2014. 
Končni protokol za študijo PASS mora biti predložen CHMP do 30. aprila 2014.
Read all of this leaflet carefully before you are given this medicine because it contains important 
Preden prejmete to zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne
Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as 
Ker se poročila o teh reakcijah poročajo prostovoljno in velikost te populacije ni znana, ne moremo realno oceniti njihove pogostnosti, zato smo jih razvrstili kot neznano.
Your doctor may decide to adjust the rate of the infusion. 
Vaš zdravnik bo morda prilagodil hitrost infuzije.
Changes in AUC only become clinically relevant in patients with moderate and severe renal impairment. 
Spremembe v AUC postanejo klinično pomembne le pri bolnikih z zmerno in hudo ledvično okvaro.
What VIBATIV is and what it is used for 2. 
Kaj je zdravilo VIBATIV in za kaj ga uporabljamo 2.
It is only used when the bacteria that cause these infections can be killed with telavancin. 
Uporablja se samo v primeru, ko je bakterije, ki so povzročile okužbo, možno uničiti s telavancinom.
If your kidneys do not work well or if you are overweight, the dose may be reduced. 
Če vaše ledvice ne delujejo dobro ali če imate prekomerno telesno maso, je odmerek lahko znižan.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. 
Prevladovanje pridobljene odpornosti lahko za izbrane vrste geografsko in sčasoma variira; zaželeni so lokalni podatki o odpornosti, še posebej pri zdravljenju hujših okužb.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. 
Zaradi pomanjkanja študij kompatibilnosti se to zdravilo ne sme mešati z drugimi zdravili, z izjemo zdravil, ki so navedena v poglavju 6.6.
The recommended dosage regimen is 10 mg/kg, once every 24 hours, for 7 to 21 days. 
Priporočeni režim odmerjanja je 10 mg/kg, na vsakih 24 ur, 7 do 21 dni.
Not known: frequency cannot be estimated from the available data severe allergic reactions (anaphylaxis). 
Neznano (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov) hude alergijske reakcije (anafilaksija).
Therefore, no dosage adjustment is necessary based on gender. 
Prilagoditev odmerka glede na spol zato ni potrebna.
Final study results by 31 May 2017 
Končni rezultati študije do 31. maja 2017
Higher concentrations were observed in alveolar macrophages with ratios varying between 0.360 (at 4 h) and 6.67 (at 24 h). 
Višje koncentracije so bile opažene pri alveolarnih makrofagih z variirajočimi razmerji med 0,360 (po 4 urah) in 6,67 (po 24 urah).
Ringing in the ears and deafness are possible side effects. 
Zvonjenje v ušesih in gluhost sta možna
While antibiotics including VIBATIV fight certain bacteria, other bacteria and fungi may continue to grow. 
Medtem ko antibiotiki, vključno z zdravilom VIBATIV, uničujejo določene bakterije, lahko druge bakterije in glivice rastejo dalje.
The results shall be reported to the CHMP on an annual basis and the final report shall be submitted no later than 31 May 2017. 
O rezultatih je treba letno poročati CHMP in končno poročilo je treba predložiti najpozneje do 31. maja 2017.
The use of VIBATIV is contraindicated during pregnancy (see section 4.3). 
Uporaba zdravila VIBATIV je med nosečnostjo kontraindicirana (glejte poglavje 4.3).
Both studies consistently showed that the area under the curve (AUC) of telavancin, but not the maximum plasma concentration (Cmax) increases with decreasing renal function. 
Obe študiji sta pokazali, da območje pod krivuljo (AUC) telavancina, ne pa tudi maksimalna koncentracija v plazmi (Cmax), narašča z upadanjem ledvične funkcije.
Final results of the study and the re-evaluation of the benefit/risk ratio for Vibativ should be provided to CHMP no later than 31 December 2017. 
Končni rezultati študije in ponovna ocenitev razmerja med koristmi in tveganji za zdravilo Vibativ morajo biti predloženi CHMP najpozneje 31. decembra 2017.
Mean (SD) AUC0-24 amounts to 780 (125) µg.h/ml. 
Povprečna (SD) AUC0-24 znaša 780 (125) µg.h/ml.
If this happens, the infusion of telavancin will be stopped and the doctor will check the functioning of your kidneys. 
Če se to zgodi, bo potrebno prekiniti infuzije telavancina, zdravnik pa bo preveril delovanje vaših ledvic.
Analysis of patient population pharmacokinetic data did not show a relevant effect of age on pharmacokinetics. 
Analiza farmakokinetičnih podatkov populacije bolnikov ni pokazala znatnega učinka starosti na farmakokinetiko.
Your doctor will monitor you for any potential infections and treat you if necessary. 
Vaš zdravnik vas bo opazoval glede možnih okužb in vas po potrebi zdravil.
All-cause mortality was 32/73 (44%) in the telavancin group and 16/64 (25%) in the vancomycin group, whereas in patients without acute renal failure at baseline it was 118/678 (17%) and 124/688 (18%), respectively. 
Skupna smrtnost je znašala 32/73 (44%) pri skupini z zdravilom telavancin in 16/64 (25%) pri skupini z vankomicinom, medtem ko je bila pri bolnikih brez akutne odpovedi ledvic v izhodišču 118/678 (17%) in 124/688 (18%).
Despite in vitro susceptibility, there are insufficient clinical data to assess the potential for efficacy of telavancin in infections due to hGISA/GISA. 
Kljub občutljivosti in vitro klinični podatki niso zadostni za ocenitev potenciala za učinkovitost telavancina pri okužbah zaradi hGISA/GISA.
Systemic macrophage hypertrophy and hyperplasia occurred in rats and dogs, in many organ systems that normally contain macrophages. 
Hipertrofija in hiperplazija sistemskih makrofagov se je pri podganah in psih pojavila v številnih organskih sistemih, ki običajno vsebujejo makrofage.
Treatment was discontinued due to adverse reactions in 5.0% of patients who received telavancin. 
Zdravljenje je bilo prekinjeno zaradi neželenih učinkov pri 5,0 % oseb, ko so prejemale telavancin.
Foaming may occur during reconstitution but will dissipate upon standing. 
Med rekonstitucijo se lahko pojavi penjenje, vendar se bo po mirovanju razpršilo.
Do not take any diarrhoea medicine without first checking with your doctor. 
Ne vzemite zdravil proti driski, ne da bi se prej posvetovali s svojim zdravnikom.
S. aureus (including methicillin-resistant strains) 
S. aureus (vključno s proti meticilinu odpornim sevom)
If superinfection occurs during therapy, appropriate measures should be taken. 
Če se superokužba pojavi med zdravljenjem, je treba uvesti ustrezne ukrepe.
The Marketing Authorisation Holder shall agree the format and content of the Healthcare Professional Guide with the National Competent Authority in the Member State. 
Imetnik dovoljenja za promet z zdravilom se dogovori o obliki in vsebini Priročnika za zdravstvene delavce s pristojnim nacionalnim organom v državi članici.
The safety and efficacy of VIBATIV in children and adolescents aged below 18 years have not yet been established. 
Varnost in učinkovitost zdravila VIBATIV pri otrocih, mlajših od 18 let, še nista bili dokazani.
• The Healthcare Professional Guide 
• Priročnik za zdravstvene delavce.
Like all medicines, VIBATIV can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo VIBATIV neželene učinke, ki pa se ne pojavijo pri vseh
The liver, kidney, macrophages and testis were identified as target organs of toxicity in animals. 
Jetra, ledvice, makrofagi in moda so bili identificirani kot ciljni organi zastrupitve pri živalih.
For storage conditions of the reconstituted or diluted medicinal product, see section 6.3. 
Za pogoje shranjevanja rekonstituiranega ali razredčenega zdravila glejte poglavje 6.3.
In combination with the small Vss, this results in a t1/2 of about 8 h. 
V kombinaciji z majhnim Vss se to kaže v razpolovnem času (t1/2) približno 8 ur.
In a mass balance study in male subjects using radiolabeled telavancin, 3 hydroxylated metabolites were identified with the predominant metabolite (THRX-651540) accounting for <10% of the radioactivity in urine and <2% of the radioactivity in plasma. 
V študiji masnega ravnotežja na moških z uporabo radioaktivno označenega telavancina, so bili s prevladujočim metabolitom (THRX-651540) identificirani 3 hidroksilni metaboliti, kar je znašalo <10 % radioaktivnosti v urinu in <2 % radioaktivnosti v plazmi.
Although telavancin does not interfere with coagulation, it interfered with certain tests used to monitor coagulation (see below), when tests are conducted using samples drawn between 0 to 18 hours after telavancin administration to patients being treated once every 24 hours. 
Čeprav telavancin ne ovira koagulacije, je oviral določene teste, ki se uporabljajo za nadzorovanje koagulacije (glejte spodaj), ko se testi izvajajo s pomočjo vzorcev, vzetih med 0 in 18 ur po dajanju telavancina bolnikom, ki prejmejo odmerek vsakih 24 ur.
In vitro experiments indicate that telavancin will not affect the clearance of medicinal products metabolised by CYP isoforms 1A2, 2C9, 2C19 and 2D6. 
In vitro poskusi kažejo, da telavancin ne bo vplival na očistek zdravil, ki jih presnavljajo izoforme CYP 1A2, 2C9, 2C19 in 2D6.
• Healthcare professionals should be aware that the administration of Vibativ may interfere with some coagulation laboratory tests and qualitative and quantitative urine protein tests. 
• Zdravstveni delavci se morajo zavedati, da lahko uporaba zdravila Vibativ vpliva na nekatere teste koagulacije ter kakovostne in količinske analize beljakovin v urinu.
Vibativ should be used with caution with other nephrotoxic medicinal products. 
Zdravilo Vibativ je treba uporabljati previdno, če uporabljate druga nefrotoksična zdravila.
Since telavancin is primarily excreted unchanged by renal clearance and multiple CYP enzymes are able to metabolise telavancin, no relevant interactions are expected with inhibitors or inducers of the CYP450 system. 
Ker se telavancin izloča predvsem nespremenjen z ledvičnim očistkom in več encimov CYP lahko presnavlja telavancin, ni pričakovati pomembnih interakcij z inhibitorji ali induktorji sistema CYP450.
Telavancin is mainly excreted unchanged accounting for approximately 82% of the total amount recovered over 48 hours in urine. 
Telavancin se v glavnem izloča nespremenjen v približno 82 % od celokupne količine, ki se v 48 urah izloči z urinom.
In vitro studies have shown that CYP1A1, 1A2, 2B6, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5 and 4F12 are able to metabolise telavancin, resulting in hydroxylation at the 7, 8 and 9 position of the 2-(decylamino) ethyl side chain of telavancin. 
In vitro študije so pokazale, da so CYP1A1, 1A2, 2B6, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5 in 4F12 zmožni presnavljati telavancin, kar vodi do hidroksilacije na 7., 8. in 9. mestu 2-(decikloamino) etilne
Women of childbearing potential have to use effective contraception during treatment. 
Ženske v rodni dobi morajo v času zdravljenja uporabljati učinkovito kontracepcijo.
The presence of hydroxypropylbetadex in the formulation at a ratio of 1:10 reduces the incidence and severity of the changes due to telavancin and attenuates the glycopeptides-like toxicity of telavancin. 
Prisotnost hidroksipropilbetadeksa v pripravku v razmerju 1:10 zmanjša pojavnost in resnost sprememb zaradi telavancina in zmanjša glikopeptidom podobno toksičnost telavancina.
The studies did not provide any evidence for a genotoxic potential of telavancin. 
Študije niso ponudile kakršnihkoli dokazov o genotoksičnem potencialu telavancina.
In healthy young adults, after infusion of radiolabeled telavancin, approximately 76% of the administered dose was recovered from urine and less than 1% of the dose was recovered from faeces (collected for up to 9 days), based on total radioactivity. 
Pri zdravih mladih odraslih osebah se je po infuziji radioaktivno označenega telavancina približno 76 % danega odmerka izločilo z urinom in manj kot 1 % odmerka z blatom (zbranih v do 9 dneh), glede na celotno radioaktivnost.
Furthermore, no evidence of hypercoagulability has been seen, as healthy subjects receiving telavancin have normal levels of D-dimer and fibrin degradation products. 
Poleg tega ni dokaza za zmožnost hiperkoagulacije, saj so imele zdrave osebe, ki so prejemale telavancin običajne ravni D-dimera in produktov razgradnje fibrina.
Telavancin has been shown to affect sperm quantity and quality of male rats (see section 5.3) although no effect on fertility, mating, or early embryogenesis has been reported. 
Telavancin dokazano vpliva na število in kakovost spermijev pri podganah (glejte poglavje 5.3), čeprav niso poročali o učinku na plodnost, parjenje ali zgodnjo embriogenezo.
Telavancin exhibited linear pharmacokinetics at doses up to 15 mg/kg administered as a daily 60 minute intravenous infusion for 7 days in healthy volunteers. 
Telavancin je pokazal linearno farmakokinetiko pri odmerkih do 15 mg/kg danih kot dnevna 60minutna intravenska infuzija zdravim prostovoljcem v 7-dnevnem obdobju.
In the event of overdose, telavancin should be discontinued and supportive care is advised with maintenance of glomerular filtration and careful monitoring of renal function. 
V primeru prekomernega odmerjanja je treba prekiniti zdravljenje s telavancinom; priporočena je podporna nega z vzdrževanjem glomerularne filtracije in pozornim nadzorom ledvične funkcije.
The tubular injury was reversible, but not all animals had yet reached full recovery 4 weeks after the end of treatment. 
Tubularna poškodba je bila reverzibilna vendar pa niso vse živali dosegle popolnega okrevanja v 4 tednih po
if you experience skin reactions to the product. 
Če imate kožne reakcije na zdravilo.
What VIBATIV is and what it is used for 
Kaj je zdravilo VIBATIV in za kaj ga uporabljamo
Telavancin must not be given to pregnant women. 
Telavancina nosečnice ne smejo dobivati.
Therefore, the same dose of 10 mg/kg/24 hr can be used in patients with normal renal function or mild renal impairment. 
Zato je mogoče uporabiti enak odmerek 10 mg/kg/24 ur pri bolnikih z normalno ledvično funkcijo ali z blago ledvično okvaro.
Telavancin demonstrated efficacy against MSSA and MRSA in two randomised controlled studies in patients with nosocomial pneumonia, including ventilator-associated pneumonia, involving 751 patients who received telavancin. 
Telavancin je dokazal učinkovitost proti MSSA in MRSA v dveh randomiziranih kontroliranih študijah pri bolnikih z bolnišnično pljučnico, vključno z ventilatorsko pljučnico, ki sta vključevali 751 bolnikov, ki so prejemali telavancin.
In vitro studies showed that telavancin retained full activity in the presence of pulmonary surfactant. 
In vitro študije so pokazale, da je telavancin zadržal polno aktivnost v prisotnosti pljučnega
If not used immediately, in use storage times are the responsibility of the user and should not be longer than 
Če ga ne porabite takoj, je za čas shranjevanja do uporabe odgovoren uporabnik, čas shranjevanja pa ne sme biti daljši od 24 ur pri
Your doctor will decide how long you should be treated. 
Vaš zdravnik se bo odločil, koliko časa bo trajalo zdravljenje.
Important information about some of the ingredients of VIBATIV This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium-free'. 
Pomembne informacije o nekaterih sestavinah zdravila VIBATIV To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar pomeni, da je v bistvu »brez
Bolus injections must not be administered. 
Bolusni odmerki se ne smejo injicirati.
For routine monitoring of renal function it is recommended to use serum creatinine concentration or estimated creatinine clearance. 
Za rutinski nadzor ledvične funkcije je priporočljiva uporaba koncentracije kreatinina v serumu ali ocenjenega očistka kreatinina.
• That there is a potential risk of teratogenicity and Vibativ is contraindicated during pregnancy. 
• Obstaja možno tveganje za teratogenost, zato je zdravilo Vibativ v času nosečnosti kontraindicirano.
It was demonstrated in a clinical study with intravenous midazolam that multiple doses of telavancin had no effect on the pharmacokinetics of midazolam, which is a sensitive substrate for CYP3A4. 
Klinična študija z intravenoznim midazolamom je pokazala, da telavancin v več odmerkih ni imel vpliva na farmakokinetiko midazolama, ki je občutljiv substrat za CYP3A4.
Acute renal failure (see section 4.4). 
Akutna ledvična odpoved (glejte poglavje 4.4).
Vacuolisation is considered to be a cytoprotective event, which is not associated with functional impairment. 
Vakuolizacijo se razume kot citoprotektiven učinek, ki ni povezan s funkcionalnim poslabšanjem.
To ensure a comparable exposure in patients with moderate renal impairment, the dose should be lowered to 7.5 mg/kg/24 hr. 
Za zagotovitev primerljive izpostavljenosti pri bolnikih z zmerno ledvično okvaro je potrebno odmerek znižati na 7,5 mg/kg/24 ur.
Your doctor may decide to reduce the dose of VIBATIV and monitor you more closely during treatment. 
Vaš zdravnik se bo morda odločil za zmanjšanje odmerka zdravila VIBATIV in vas bo med zdravljenjem podrobneje opazoval.
S. aureus that exhibit high level resistance to glycopeptide antibacterial agents (GRSA) are not susceptible to telavancin. 
S. aureus, ki kaže visoko raven odpornosti na glikopeptidne antibiotike (GRSA), ni občutljiv na telavancin.
if you develop diarrhoea during or shortly after your treatment, tell your doctor immediately. 
Če med zdravljenjem ali kmalu po zdravljenju dobite drisko, o tem nemudoma obvestite zdravnika.
Telavancin is active against Gram-positive bacteria only (see section 5.1 for information on the antimicrobial spectrum). 
Telavancin deluje izključno proti grampozitivnim bakterijam (glejte poglavje 5.1 za podatke o antibakterijskem spektru).
Elderly patients should receive a telavancin dose in accordance with their bodyweight and renal function (see sections 4.3 and 5.2). 
Starejši bolniki prejmejo odmerek telavancina glede na njihovo telesno maso in ledvično funkcijo (glejte poglavji 4.3 in 5.2).
At higher doses or longer treatment durations, vacuolisation of the urothelium in the bladder also occurred. 
Pri višjem odmerku in daljšem zdravljenju, se je prav tako pojavila vakuolizacija urotelija v mehurju.
Vacuolisation was not associated with renal function impairment, but was not reversible after 4 weeks of recovery. 
Vakuolizacija ni bila povezana z okvaro ledvične funkcije, vendar ni bila odpravljena po 4 tednih okrevanja.
Renal excretion is the major route of elimination for telavancin in humans. 
Izločanje preko ledvic je glavni način izločanja telavancina pri ljudeh.
Mild to moderate degrees of hepatic impairment (Child-Pugh class B) (see section 5.2) did not result in a relevant change in pharmacokinetics of telavancin. 
Blage do zmerne stopnje okvare jeter (Child-Pugh razred B) (glejte poglavje 5.2) niso pomembno spremenile farmakokinetike telavancina.
Telavancin is not to be used in children or adolescents under 18 years of age. 
Telavancina ne smete uporabljati pri otrocih in mladostnikih, ki so mlajši od 18 let.
Patients with these conditions were not included in clinical trials of telavancin. 
Bolniki s temi obolenji niso bili vključeni v klinična preskušanja telavancina.
At a dose of 10 mg/kg for 3 consecutive days to healthy volunteers subjected to bronchoalveolar lavage, the concentration ratio in pulmonary epithelial lining fluid/plasma ranged from 0.050 and 0.121 over a period of 4 to 24 hours after start of infusion. 
Pri odmerku 10 mg/kg v 3 zaporednih dneh zdravim prostovoljcem, pri katerih so delali bronhoalveolarno izpiranje, je bilo razmerje koncentracije med tekočino v pljučnem epitelnem sloju in plazmo od 0,050 do 0,121 v času od 4 do 24 ur po začetku infundiranja.
The excretion of telavancin in milk has not been studied in animals. 
Izločanje telavancina v mleku pri živalih ni preučeno.
Vacuolisation is considered to represent a cytoprotective event and is expected to reverse with the same half-life as the turnover time of the proximal tubular cells. 
Vakuolizacija naj bi predstavljala dogodek celične zaščite in naj bi bila odpravljena z enako razpolovno dobo kot je čas nadomestitve proksimalnih tubularnih celic.
• That the benefit risk balance for the Complicated Skin and Soft Tissue Infections indication was assessed as negative by the Committee for Medicinal Products for Human Use (CHMP), therefore Vibativ should not be used in this or other indications not approved. 
• Odbor za zdravila za uporabo v humani medicini (CHMP) je ocenil razmerje med koristmi in tveganji za indikacijo zapletenih okužb kože in mehkega tkiva kot negativno, zato se zdravilo Vibativ ne sme uporabljati za to in za druge neodobrene indikacije.
Dosage regimen 
Režim odmerjanja
if you are allergic (hypersensitive) to telavancin or any of the other ingredients of VIBATIV If you suffer from severe kidney problems, or receive haemodialysis 
če ste alergični (preobčutljivi) na telavancin ali katerokoli sestavino zdravila VIBATIV če imate hude težave z ledvicami ali če ste na hemodializi